 |
|
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
Chung-Feng Huang, Ming-Lung Yu
Clin Mol Hepatol. 2020;26(3):251-260. Published online 2020 Mar 19 DOI: https://doi.org/10.3350/cmh.2020.0018
|
|
Citations to this article as recorded by
 Toward hepatitis C virus elimination using artificial intelligence
Moon Haeng Hur, Jeong-Hoon Lee
Clinical and Molecular Hepatology.2024; 30(2): 147. CrossRef Strategies of hepatitis C virus elimination for people who inject drugs receiving opioid agonist therapy in the era of direct‐acting antivirals
Fai‐Meng Sou, Chien‐Hung Chen, Pao‐Yuan Huang, Ming‐Chao Tsai, Yi‐Hao Yen, Sheng‐Nan Lu, Chao‐Hung Hung, Yuan‐Hung Kuo
Advances in Digestive Medicine.2024;[Epub] CrossRef Synthesis of novel azasugar-containing 2'β-C-Me 9-deaza nucleosides as potential anti-hepatitis C virus agents
Pravin L. Kotian, Minwan Wu, Ajit Ghosh, Kevin J. Polach, Yahya El-Kattan, V. Satish Kumar, Tsu-Hsing Lin, Xiaogang Cheng, Shanta Bantia, Krishnan Raman, Pooran Chand, Yarlagadda S. Babu
Nucleosides, Nucleotides & Nucleic Acids.2023; 42(4): 317. CrossRef Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan – A multi-center collaborative care model
Ching-Chu Lo, Wei-Yi Lei, Ying-Che Huang, Jow-Jyh Hwang, Chen-Yu Lo, Chien-hung Lin, Hsu-sheng Cheng, Yee-Tam Liao, Po-Cheng Liang, Meng-Jau Chiou, Ming-Jong Bair, Chia-Yen Dai, Ming-Lung Yu
Journal of Microbiology, Immunology and Infection.2023; 56(4): 680. CrossRef Gastrointestinal functional disorders can benefit from the use of medical devices made of substances
Vincenzo Savarino, Elisa Marabotto, Patrizia Zentilin, Manuele Furnari, Giorgia Bodini, Edoardo Giovanni Giannini, Edoardo Vincenzo Savarino
Frontiers in Drug Safety and Regulation.2023;[Epub] CrossRef A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic
Ching-I Huang, Po-Cheng Liang, Yu-Ju Wei, Pei-Chien Tsai, Po-Yao Hsu, Ming-Yen Hsieh, Ta-Wei Liu, Yi-Hung Lin, Meng-Hsuan Hsieh, Tyng-Yuan Jang, Chih-Wen Wang, Jeng-Fu Yang, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, Ming
Journal of Microbiology, Immunology and Infection.2023; 56(3): 586. CrossRef Human Mesenchymal Stem Cells Modified with the NS5A Gene of Hepatitis C Virus Induce a Cellular Immune Response Exceeding the Response to DNA Immunization with This Gene
Olga V. Masalova, Ekaterina I. Lesnova, Vladimir A. Kalsin, Regina R. Klimova, Natalya E. Fedorova, Vyacheslav V. Kozlov, Natalya A. Demidova, Kirill I. Yurlov, Mikhail A. Konoplyannikov, Tatyana N. Nikolaeva, Alexander V. Pronin, Vladimir P. Baklaushev,
Biology.2023; 12(6): 792. CrossRef A Vermont Statewide Educational Intervention to Improve Access to Hepatitis C Virus Treatment in a Rural State
Andrew J. Hale, Steven D. Lidofsky
Journal of Medical Education and Curricular Development.2023;[Epub] CrossRef Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
Naim Abu-Freha, Osama Abu-Kosh, David Yardeni, Yaffa Ashur, Muhammad Abu-Arar, Baha Yousef, Shulamit Monitin, Sarah Weissmann, Ohad Etzion
Life.2023; 13(9): 1872. CrossRef Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
Ming-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, Chi‐Ming Tai, Lein-Ray Mo, Hsing-Tao Kuo, Kuo-Chih Tseng, Ching-Chu Lo, Ming-Jong Bair, Szu-Jen Wang, Jee-Fu Huang, Ming-Lun Yeh, Chun-Ting Chen, Ming-Chang Tsai, Chien-Wei Huang, Pei-Lun Lee, Tzeng-Hue Yang
Clinical and Molecular Hepatology.2023; 30(1): 64. CrossRef Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
Po‐Yao Hsu, Tzu‐Sheng Cheng, Shih‐Chang Chuang, Wen‐Tsan Chang, Po‐Cheng Liang, Cheng‐Ting Hsu, Yu‐Ju Wei, Tyng‐Yuan Jang, Ming‐Lun Yeh, Ching‐I Huang, Yi‐Hung Lin, Chih‐Wen Wang, Ming‐Yen Hsieh, Nai‐Jen Hou, Meng‐Hsuan Hsieh, Yi‐Shan Tsai, Yu‐Min Ko, Chi
Cancer Medicine.2022; 11(1): 104. CrossRef Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison
Chun-Ting Chen, Ming-Ying Lu, Meng-Hsuan Hsieh, Pei-Chien Tsai, Tsai-Yuan Hsieh, Ming-Lun Yeh, Ching-I Huang, Yi-Shan Tsai, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Yu-Ju Wei, Po-Yao Hsu, Cheng-Ting Hsu, Tyng-Yuan Jang, Ta-Wei Liu, Po-Cheng Liang, Ming-Ye
World Journal of Gastroenterology.2022; 28(2): 263. CrossRef Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan
Ching-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, Kuo-Chih Tseng, Chi-Yi Chen, Hsing-Tao Kuo, Yi-Hsiang Huang, Chi-Ming Tai, Cheng-Yuan Peng, Ming-Jong Bair, Chien-Hung Chen, Ming-Lun Yeh, Chih-Lang Lin, Chun-Yen Lin, Pei-Lun Lee, Lee-Won Chong, Chao-Hung Hu
Journal of the Formosan Medical Association.2022; 121(8): 1567. CrossRef Combination of dasabuvir and PSI-6206 for the treatment of coxsackievirus B3 infection
Oluwatayo Israel Olasunkanmi, Zhao-Hua Zhong
Journal of Virus Eradication.2022; 8(2): 100074. CrossRef Milestones in the discovery of hepatitis C
Octavio Campollo, Gerardo Amaya, P Aiden McCormick
World Journal of Gastroenterology.2022; 28(37): 5395. CrossRef A People-Centered Decentralized Outreach Model Toward HCV Micro-Elimination in Hyperendemic Areas: COMPACT Study in SARS Co-V2 Pandemic
Ching-i Huang, Po-Cheng Liang, Yu-Ju Wei, Pei-Chien Tsai, Po-Yao Hsu, Ming-Yen Hsieh, Ta-Wei Liu, Yi-Hung Lin, Meng-Hsuan Hsieh, Tyng-Yuan Jang, Chih-Wen Wang, Jeng-Fu Yang, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, Ming
SSRN Electronic Journal .2022;[Epub] CrossRef Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C)
Ming-Lung Yu, Chung-Feng Huang, Yu-Ju Wei, Wen-Yi Lin, Yi-Hung Lin, Po-Yao Hsu, Cheng-Ting Hsu, Ta Wei Liu, Jia-Jung Lee, Sheng-Wen Niu, Jiun-Chi Huang, Tzu-Sui Hung, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Ming-Yen Hsieh, Szu-Chia Chen, Jee-Fu Huang
Gut.2021; 70(12): 2349. CrossRef Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020
Ming‐Lung Yu, Wan‐Long Chuang
The Kaohsiung Journal of Medical Sciences.2021; 37(1): 7. CrossRef Elbasvir and grazoprevir for the treatment of hepatitis C
Szu-Jen Wang, Chung-Feng Huang, Ming-Lung Yu
Expert Review of Anti-infective Therapy.2021; 19(9): 1071. CrossRef Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
Chung-Feng Huang, Pey-Fang Wu, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Cheng-Ting Hsu, Po-Yao Hsu, Hung-Yin Liu, Ying-Chou Huang, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu
Clinical and Molecular Hepatology.2021; 27(1): 136. CrossRef Drug-drug interactions with direct-acting antivirals — less is more
Grace Lai-Hung Wong
Clinical and Molecular Hepatology.2021; 27(1): 81. CrossRef Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care
Seong Hee Kang, Moon Young Kim
Clinical and Molecular Hepatology.2021; 27(1): 100. CrossRef The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients
Yu Jun Wong, Prem Harichander Thurairajah, Rahul Kumar, Kwong Ming Fock, Ngai Moh Law, Sin-Yoong Chong, Fria Gloriba Manejero, Tiing-Leong Ang, Eng Kiong Teo, Jessica Tan
Clinical and Molecular Hepatology.2021; 27(3): 474. CrossRef Future outcomes and health needs of chronic hepatitis C patients after receiving antiviral therapy
Yu‐Hsuan Hsiao, Wei‐Ming Chen, Chia‐Hao Chang, Mei‐Yen Chen
Journal of Advanced Nursing.2021; 77(8): 3370. CrossRef Achieving HCV micro-elimination in rural communities
Shannon J Brown, Linh T Cosgrove, Samuel S Lee
Canadian Liver Journal.2021; 4(1): 1. CrossRef Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan
Chi‐Yi Chen, Chung‐Feng Huang, Pin‐Nan Cheng, Kuo‐Chih Tseng, Ching‐Chu Lo, Hsing‐Tao Kuo, Yi‐Hsiang Huang, Chi‐Ming Tai, Cheng‐Yuan Peng, Ming‐Jong Bair, Chien‐Hung Chen, Ming‐Lun Yeh, Chih‐Lang Lin, Chun‐Yen Lin, Pei‐Lun Lee, Lee‐Won Chong, Chao‐Hung Hu
Liver International.2021; 41(6): 1265. CrossRef Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea
Jae Seung Lee, Hong Jun Choi, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
Journal of Gastroenterology and Hepatology.2021; 36(9): 2479. CrossRef Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
Ming-Lun Yeh, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Chi-Yi Chen, Hsing-Tao Kuo, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Rong-Nan Chien, Chi-Chieh Yang, Gin-Ho Lo, Chi‐Ming Tai, Chih-Wen Lin, Jia-Horng Kao, Chen-Hua Liu, Sheng-Lei Yan, Ming-J
Hepatology International.2021; 15(5): 1109. CrossRef Differential Expression of the Host Lipid Regulators ANGPTL-3 and ANGPTL-4 in HCV Infection and Treatment
Vaia Valiakou, Petros Eliadis, Eirini Karamichali, Ourania Tsitsilonis, John Koskinas, Urania Georgopoulou, Pelagia Foka
International Journal of Molecular Sciences.2021; 22(15): 7961. CrossRef Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection
Hung-Yin Liu, Yi-Hung Lin, Pei-Ju Lin, Pei-Chien Tsai, Shu-Fen Liu, Ying-Chou Huang, Jia-Jiun Tsai, Ching-I Huang, Ming-Lun Yeh, Po-Cheng Liang, Zu-Yau Lin, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Chung-Feng Huang, Ming-Lung Yu, Tatsuo Kanda
PLOS ONE.2021; 16(7): e0254028. CrossRef In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?
Natalia Echeverría, Victoria Comas, Fabián Aldunate, Paula Perbolianachis, Pilar Moreno, Juan Cristina
World Journal of Hepatology.2021; 13(10): 1234. CrossRef Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report
Fabián Aldunate, Natalia Echeverría, Daniela Chiodi, Pablo López, Adriana Sánchez-Cicerón, Martín Soñora, Juan Cristina, Gonzalo Moratorio, Nelia Hernández, Pilar Moreno
BMC Infectious Diseases.2021;[Epub] CrossRef Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study
Dong Hyun Sinn, Danbee Kang, Yun Soo Hong, Kwang Cheol Koh, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak, Luca Rinaldi
PLOS ONE.2021; 16(8): e0255624. CrossRef Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
Chung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, Ching-Chu Lo, Chao-Hung Hung, Chien-Wei Huang, Lee-Won Chong, Pin-Nan Cheng, Ming-Lun Yeh, Cheng-Yuan Peng, Chien-Yu Cheng, Jee-Fu Huang, Ming-Jong Bair, Chih-Lang Lin, Chi-Chieh Yang, Szu-Jen Wang, Tsai-Yu
Scientific Reports.2021;[Epub] CrossRef Difluoromethylornithine (DFMO), an Inhibitor of Polyamine Biosynthesis, and Antioxidant N-Acetylcysteine Potentiate Immune Response in Mice to the Recombinant Hepatitis C Virus NS5B Protein
Ekaterina I. Lesnova, Olga V. Masalova, Kristina Yu. Permyakova, Vyacheslav V. Kozlov, Tatyana N. Nikolaeva, Alexander V. Pronin, Vladimir T. Valuev-Elliston, Alexander V. Ivanov, Alla A. Kushch
International Journal of Molecular Sciences.2021; 22(13): 6892. CrossRef HCV RNA in serum and liver samples of patients undergoing living donor liver transplantation
Shu-Hsien Lin, Kun-Ta Wu, Chih-Chi Wang, Kuang-Tzu Huang, Kuang-Den Chen, Chih-Che Lin, Li-Wen Hsu, King-Wah Chiu
Journal of International Medical Research.2021; 49(8): 030006052110349. CrossRef Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement
Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Alex Thompson, Jidong Jia, Jinlin Hou, Cosmas Rinaldi Adithya Lesmana, Adityo Susilo, Yasuhito Tanaka, Wah-Kheong Chan, Ed Gane, Arlinking K Ong-Go, Seng-Gee Lim, Sang Hoon Ahn, Ming-Lung Yu, Teerha Piratvisuth,
The Lancet Gastroenterology & Hepatology.2020; 5(8): 776. CrossRef Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
Sara Kishta, Ashraf Tabll, Tea Omanovic Kolaric, Robert Smolic, Martina Smolic
Biomedicines.2020; 8(6): 175. CrossRef High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy
Wei-Ming Chen, Kuo-Liang Wei, Shui-Yi Tung, Chien-Heng Shen, Te-Sheng Chang, Chih-Wei Yen, Yung-Yu Hsieh, Wen Nan Chiu, Jin Hung Hu, Sheng-Nan Lu, Chao-Hung Hung
Journal of the Formosan Medical Association.2020; 119(11): 1593. CrossRef Infectious diseases of the hepatobiliary system
Rachel Mary Brown
Diagnostic Histopathology.2020; 26(12): 566. CrossRef Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
Cancers.2020; 12(11): 3414. CrossRef
|